Blau Farmaceutica S.A.
7
0
0
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
14.3%
1 terminated/withdrawn out of 7 trials
66.7%
-19.8% vs industry average
43%
3 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Evaluation of the Pharmacodynamics of a Heparin With Its Biological Comparator, Subcutaneous Administration
Role: lead
Evaluation of the Pharmacodynamics of a Heparin With Its Biological Comparator, Intravenous Administration
Role: lead
Effectiveness and Safety Study of Filgrastine® in Patientes With Breast Cancer Treated With Myelotoxic Chemotherapy
Role: lead
Asses the Impact of Early Starting Erythropoetin in the Reduction of Transfusions Blood in Childrens
Role: lead
Pharmacokinetics and Pharmacodynamics Assessment of Drug Eritromax Compared to Eprex in Healthy Subjects.
Role: collaborator
Pharmacodynamics Study of Enoxalow Compared to Clexane in Healthy Subjects After Intravenous Administration
Role: collaborator
Clinical Efficacy of Two Erythropoietin Drug in Participants With Secondary Anemia to Chronic Kidney Disease.
Role: collaborator
All 7 trials loaded